Spots Global Cancer Trial Database for HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China
Official Title: Superselective Drug-Eluting Chemoembolization With HepaSphere in Unresectable Advanced HCC Patients: Safety & Efficacy Registry in China (SUPER-China)
Study ID: NCT02743065
Conditions
Interventions
Study Description
Brief Summary: The purpose of this multicenter registry is to gather the safety, efficacy and survival data in advanced HCC patients treated with HepaSphere in China in order to evaluate the application of HepaSphere deTACE in treating advanced HCC patients
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Hospital Chinese Academy of Medical Science, Beijing, , China
Peking Union Medical College Hospital, Beijing, , China
Fifth Affiliated Hospiatl, Sun Yet-Sen University, Guangzhou, , China
Nanfang Hospital, Southern Medical University, Guangzhou, , China
Third Affiliated Hospiatl, Sun Yet-Sen Hospital, Guangzhou, , China
Zhongshan Hospital, Fudan University, Shanghai, , China
Contact Details
Name: Hong Shan, MD
Affiliation: Fifth Affiliated Hospiatl, Sun Yet-Sen University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
